<DOC>
	<DOCNO>NCT02281214</DOCNO>
	<brief_summary>The identification driver mutation epidermal growth factor receptor ( EGFR ) primary oncogenic event subset lung adenocarcinoma lead model target treatment genetic profiling disease . EGFR tyrosine kinase inhibitor ( TKIs ) confer remission patient , use EGFR-TKIs limited patient adenocarcinomas know activate EGFR mutation . And resistance TKI treatment become increasingly important cause treatment failure . Therefore , identification molecular component involve could lead development effective therapy . Today limit number genetic alteration study . Next Generation Sequencing ( NGS ) potential become important tool clinical therapeutic decision-making oncology owe enhanced sensitivity DND mutation detection .</brief_summary>
	<brief_title>NGS Genome Analysis Personalisation Lung Cancer Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>patient bronchial adénocarcinoma metastasis benefit firstline therapy target therapy tyrosine kinase inhibitor ( TKI ) EGFR mutation chemotherapy non EGFR mutation ) Patients epidermoid cancer lung benefit chemotherapy man woman age ≥ 18 year Patients sign write informed consent form Patients affiliated social health insurance Survival time ≤ 3 month Patients cerebral metastasis Patients could benefit treatment others diseases Pregnancy breastfeed Incapacity sign consent form psychiatric , behavioural disorder Private individual freedom tutelage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>lung cancer , mutation</keyword>
	<keyword>patient</keyword>
	<keyword>mutation</keyword>
</DOC>